www.biondvax.com Open in urlscan Pro
198.185.159.144  Public Scan

Form analysis
0 forms found in the DOM

Text Content

0

Click here to view a recording of our April 4, 2022 Analyst & Investor Webinar

Skip to Content


Home
About
BiondVax
Management
Board of Directors
Scientific Advisory Board
Clinical Trials
Product Development
NanoAbs
CDMO
Media
Press Releases
In the News
Investors
Investors
Events
Financial Information
Investor FAQs
Analyst Coverage
Careers

Open Menu Close Menu

Home
About
BiondVax
Management
Board of Directors
Scientific Advisory Board
Clinical Trials
Product Development
NanoAbs
CDMO
Media
Press Releases
In the News
Investors
Investors
Events
Financial Information
Investor FAQs
Analyst Coverage
Careers

Open Menu Close Menu

Home
Folder: About
Folder: Product Development
Folder: Media
Folder: Investors
Careers

Back
BiondVax
Management
Board of Directors
Scientific Advisory Board
Clinical Trials
Back
NanoAbs
CDMO
Back
Press Releases
In the News
Back
Investors
Events
Financial Information
Investor FAQs
Analyst Coverage


BIONDVAX IS DEVELOPING A PIPELINE OF INNOVATIVE NANOSIZED ANTIBODY (NANOAB)
THERAPIES ADDRESSING DISEASES SUCH AS COVID-19, ASTHMA, AND PSORIASIS

COLLABORATION WITH MAX PLANCK & UMG

GMP BIOLOGICS MANUFACTURING FACILITY

EXTENSIVE DRUG DEVELOPMENT EXPERTISE

TOP-TIER PHARMA LEADERSHIP

RECENT NEWS

Featured

11 Oct 2022

BiondVax to present at LD Micro Investor Conference in Los Angeles
11 Oct 2022

11 Oct 2022

30 Sep 2022

BiondVax announces financial plans to support its ongoing NanoAb pipeline
development
30 Sep 2022

30 Sep 2022

20 Sep 2022

BiondVax’s Strategic Research Collaboration: Significant progress towards
development of innovative nanosized antibodies (NanoAbs) for therapeutic
indications in addition to COVID-19
20 Sep 2022

20 Sep 2022

8 Sep 2022

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
8 Sep 2022

8 Sep 2022




OUR MISSION: TO HELP BUILD A HEALTHIER AND HAPPIER WORLD BY DEVELOPING,
MANUFACTURING AND COMMERCIALIZING PRODUCTS FOR THE PREVENTION AND TREATMENT OF
INFECTIOUS DISEASES AND OTHER ILLNESSES.


BIONDVAX’S ASSETS, CAPABILITIES AND EXPERIENCE POSITION US WELL FOR
IN-LICENSING, ACQUISITIONS, AND JOINT VENTURES & RAPID CLINICAL DEVELOPMENT AND
MANUFACTURING OF NEW THERAPEUTIC AND PROPHYLACTIC TECHNOLOGIES.

 


EXPERIENCE

VACCINE DEVELOPMENT

 * Extensive experience in vaccine development from preclinical through multiple
   clinical trials

 * Phase 3 clinical trial for influenza vaccine candidate in over 12,400
   participants, 105 sites and seven countries was completed on time and on
   budget in the face of the growing threat of COVID-19


ASSETS

LEADERSHIP, CAPITAL & MANUFACTURING

 * Big pharma experienced leadership team including Chairman (Alexion), CEO
   (Novartis and GSK), Board director (BMS), COO (Novartis)

 * GMP biologics manufacturing facility in Jerusalem, Israel

 * Support from European Investment Bank (EIB) with €24m in non-dilutive
   financing, the first such agreement with a non-EU company

 * US publicly traded company on Nasdaq: BVXV


ACTIVITIES

PIPELINE DEVELOPMENT

 * Collaboration with Max Planck Society and University Medical Center
   Göttingen, Germany for a broad-based strategic collaboration towards a new
   nanosized antibody (NanoAb) pipeline beginning with COVID-19

 * Exploring additional alternatives towards development of a diverse and robust
   multi-asset pipeline

 

Copyright 2022 BiondVax Pharmaceuticals Ltd. All Rights Reserved | Terms &
Conditions | Privacy Policy | Code of Ethics | Contact

 



By using this website, you agree to our use of cookies. We use cookies to
provide you with a great experience and to help our website run effectively.

Accept